Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP)

Annals of Surgical Oncology

Volumn 6, Issue 6, 1999, Pages 582-590

  Park, Bernard J ^a   Alexander, H Richard ^a   Libutti, Steven K ^a   Wu, Peter ^a   Royalty, Dan ^a   Kranda, Karen C ^a   Bartlett, David L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Carcinomatosis; Continuous hyperthermic peritoneal perfusion (CHPP); Intraperitoneal cisplatin; Primary peritoneal mesothelioma; Tumor necrosis factor

Indexed keywords

CISPLATIN; FLUOROURACIL; PACLITAXEL; PLATINOL 7; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; ASCITES; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HYPERTHERMIC THERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROTOXICITY; PERFUSION; PERITONEUM MESOTHELIOMA; PHASE 1 CLINICAL TRIAL; RECURRENT CANCER; SEPSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032868873     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0582-6     Document Type: Article

References (35)

1. Connelly RR, Spirtas R, Myers MH, et al. Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 1987; 78:1053.
2. Averbach AM, Sugarbaker PH. Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treat Res 1996; 81:193-211.
3. van Gelder T, Hoogsteden HC, Versnel MA, et al. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 1989;43: 222-7.
4. Moertel C. Peritoneal mesothelioma. Gastroenterology 1972;63: 346-50.
5. Antman KH, Blum RH, Greenberger JS, et al. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980;68:356-62.
6. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988;6:147-53.
7. Antman KH, Pass HI, Recht A. Benign and malignant mesothelioma. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer: Principles and practice of oncology. Philadelphia: Lippincott, 1989: 1399-417.
8. Plaus WJ. Peritoneal mesothelioma. Arch Surg 1988;123:763-6.
9. Falkson G, Hunt M, Borden EC, et al. An extended phase II trial of ifosfamide plus mesma in malignant mesothelioma. Invest New Drugs 1992;10:337-43.
10. Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985;XII:1-6.
11. Markman M. Intraperitoneal paclitaxel in the management of ovarian cancer. Semin Oncol 1995;22:86-7.
12. Antman K, Osteen R, Klegar K, et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet 1985;2:977-81.
13. Lederman GS, Recht A, Herman T, et al. Long-term survival in peritoneal mesothelioma: the role of radiotherapy and combined modality treatment. Cancer 1987;59:1882-6.
14. Alexander HR, Fraker DL. Continuous hyperthermic peritoneal perfusion with cisplatin in the treatment of peritoneal carcinomatosis. Reg Cancer Treat 1995;8:2-7.
15. Fujimoto S, Shgrestha RD, Kokubun M, et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 1988;208:36-41.
16. Fujimura T, Yonemura Y, Fushida S, et al. Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 1990;65:65-71.
17. Koga S, Hamazoe R, Maeta M, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988;61:232-7.
18. Bartlett DL, Buell JF, Libutti SK, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998;83:1251-61.
19. Ma GY, Bartlett DL, Reed E, et al. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am 1997;3:174-9.
20. Alexander HR, Buell JF, Fraker DL. Rationale and clinical status of continuous hyperthermic peritoneal perfusion (CHPP) for the treatment of peritoneal carcinomatosis. In: DeVita V, Hellman S, Rosenberg S, eds. Principles and practices of oncology updates. Philadelphia: J.B. Lippincott, 1995:1-9.
21. Howell SB, Pfeifle CE, Wung WE, et al. Intiaperitoneal cisdiamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 1983;43:1426-31.
22. Howell SB, Pfeifle CG, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97:845-51.
23. Vogelzang NJ. Malignant mesothelioma: diagnostic and management strategies for 1992. Semin Oncol 1992;19:64-71.
24. Asensio JA, Goldblatt P, Thomford NR. Primary malignant peritoneal mesothelioma. Arch Surg 1990;125:1477-81.
25. Markman M, Cleary S, Pfeifle C, et al. Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 1986;58:18-21.
26. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992;118:547-50.
27. Gilly FN, Carry PY, Sayag AC, et al. Regional chemotherapy (with Mitomycin C) and infra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 1994;41:124-9.
28. Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg 1994;18:150-5.
29. Yonemura Y, Fujimura T, Nishimura G, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996;119:437-44.
30. 2 with i.v. sodium thiosulfate. JAMA 1989;16:84-6.
31. Barlogie B, Cony PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-Dichlorodiammineplatinum(II) and Mitomycin C. Cancer Res 1980;40:1165-8.
32. Ajani JA, Ilson DH, Kelsen DP. The activity of paclitaxel in gastrointestinal tumors. Semin Oncol 1995;22:46-50.
33. Howell SB, Zimm S, Markman M, et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987;5:1607-12.
34. Schwartz E, Maayan C, Mouallem M, et al. Malignant peritoneal mesothelioma: long-term spontaneous clinical remission. Med Pediatr Oncol 1991;19:325-8.
35. Norman PE, Whitaker D. Nine-year survival in a case of untreated peritoneal mesothelioma. Med J Aust 1989;150:43-4.